-
Study aim
-
The aim of this study is to evaluate the effectiveness of a specific analgesic protocol in patients undergoing surgery for zygomaticomaxillary complex (ZMC) fractures.
-
Design
-
A triple-blind, randomized controlled trial was conducted on 80 patients with ZMC fractures. Participants were randomly assigned to Montelukast and control groups (n=40 each), using a random numbers table. Each group was further divided into four subgroups (n=10) based on timing of drug administration (0, 6, 12, or 24 hours before surgery). Randomization and allocation concealment were performed using a random starting point in the table.
-
Settings and conduct
-
Randomization was performed using a random number table; patients, surgeons, and data analysts were blinded, while only the anesthesiologist and dental student preparing the medication were aware of group assignments.
-
Participants/Inclusion and exclusion criteria
-
Individuals aged 18 to 60 years, of either gender, with a body mass index of less than 30 kg/m² (non-obese), with ZMC fractures, who present to the maxillofacial surgery department of the hospital for treatment.
Exclusion criteria include: preoperative use or dependence on narcotic substances, peptic ulcer disease, hepatic or renal dysfunction, psychiatric disorders, allergy to amide local anesthetics or opioids, and a history of seizures.
-
Intervention groups
-
The effect of a single preoperative oral dose of Montelukast (10 mg) on postoperative pain intensity in patients undergoing surgery for ZMC fractures. Eighty patients will be randomly assigned to four experimental and four control subgroups based on the timing of drug administration (0, 6, 12, or 24 hours before surgery).
-
Main outcome variables
-
Timing of montelukast administration before surgery, amount of analgesic consumption after surgery, and patient satisfaction with pain management.